Albany Molecular Research (AMRI) Settles Patent Infringement Litigation Involving Allegra(R)
More News related to AMRI
- Albany Molecular Research (AMRI) Posts Q3 Loss of $0.02, Tops by 2c; Guides
- AMRI Announces Third Quarter 2009 Results
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
- AMRI to Present at the Oppenheimer 20th Annual Healthcare Conference
More News related to BRL
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Bearclaw Announces That Silver Quest Has Earned Interest in Capoose Property
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Pharmaceutical (TEVA) and Bar Pharma (BRL) Receives Merger Approval From European Commission
More News related to SNY
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
More News related to Corporate News
- Schlumberger (SLB) and Alstom SA Sign Agreement to Study Carbon Capture and Storage Systems
- RADCOM's (RDCM) Omni-Q Monitoring System Selected by Major Asian Cellular Operator
- LDK Solar (LDK) Announces Civil Order to Freeze Any Payments to Guarantee Banks From Q-Cell Payments
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
Albany Molecular Research, Inc. (NASDAQ: AMRI) and its wholly owned subsidiary, AMR Technology, Inc., announced that a settlement regarding U.S. patent infringement litigation involving ALLEGRA(R) and ALLEGRA(R)D-12 has been reached among them, Aventis Pharmaceuticals, Inc., sanofi-aventis (NYSE: SNY), Teva Pharmaceuticals, USA, Inc. (Nasdaq: TEVA) and Barr Laboratories, Inc. (NYSE: BRL). The settlement agreement and related licensing arrangements are subject to review by the Federal Trade Commission and U.S. state Attorneys General.
As part of the settlement, AMRI has entered into an amendment to its licensing agreement with sanofi-aventis to allow sanofi-aventis to sublicense patents related to ALLEGRA(R) and ALLEGRA(R)D-12 to Teva Pharmaceuticals, USA, Inc. and Barr Laboratories, Inc. in the United States. AMRI will receive an upfront sublicense fee from sanofi-aventis U.S. LLC of $10 million.
Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies in the United States and internationally.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
